Literature DB >> 30160806

Arg399Gln substitution in XRCC1 as a prognostic and predictive biomarker for prostate cancer: Evidence from 8662 subjects and a structural analysis.

Mahdi Noureddini1,2, Narges Mobasseri3, Mohammad Karimian3, Mohaddeseh Behjati4, Hossein Nikzad5.   

Abstract

BACKGROUND: The Arg399Gln polymorphism in the X-ray repair cross-complementing group 1 gene (XRCC1) may alter the risk of prostate cancer (PCa). The present study aimed to investigate the association of the XRCC1-Arg399Gln polymorphism with PCa risk in an Iranian population, as followed by a meta-analysis and an in silico analysis.
METHODS: In a case-control study, 360 subjects were included (180 men with PCa and 180 healthy controls). XRCC1-Arg399Gln genotyping was performed using the polymerase chain reaction-restriction fragment length polymorphism method. In the meta-analysis, 14 eligible studies were included to which our case-control data were added to estimate the pooled odds ratios. Some bioinformatics tools were employed to evaluate the effects of Arg399Gln substitution on molecular aspects of the XRCC1 protein.
RESULTS: Our case-control study revealed a significant association between the XRCC1-Arg399Gln polymorphism and PCa risk. The data from overall meta-analysis showed significant associations between the mentioned polymorphism and PCa risk in allelic and recessive genetic models. In addition, we observed statistically significant associations in stratified analyses by ethnicity, sample size and source of controls. Our in silico analysis showed that Arg399Gln substitution could be damaging with respect to the function and structure of the XRCC1 protein.
CONCLUSIONS: Based on these results, the XRCC1-Arg399Gln polymorphism might be a risk factor for PCa and it could be considered as a prognostic and predictive biomarker for susceptible men.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  XRCC1 gene; in silico analysis; meta-analysis; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 30160806     DOI: 10.1002/jgm.3053

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  6 in total

1.  Association of PON1-L55M Genetic Variation and Breast Cancer Risk: A Case-Control Trial.

Authors:  Amir Farmohammadi; Ali Momeni; Banafshe Bahmani; Hossein Ghorbani; Ramin Ramzanpour
Journal:  Asian Pac J Cancer Prev       Date:  2020-01-01

2.  Androgen receptor (AR)-CAG trinucleotide repeat length and idiopathic male infertility: a case-control trial and a meta-analysis.

Authors:  Narges Mobasseri; Faezeh Babaei; Mohammad Karimian; Hossein Nikzad
Journal:  EXCLI J       Date:  2018-12-17       Impact factor: 4.068

3.  Methionine Synthase Reductase-A66G and -C524T Single Nucleotide Polymorphisms and Prostate Cancer: A Case-Control Trial

Authors:  Atefeh Basir
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25

4.  Association analysis of rs1695 and rs1138272 variations in GSTP1 gene and breast cancer susceptibility.

Authors:  Amir Farmohammadi; Vahid Arab-Yarmohammadi; Ramin Ramzanpour
Journal:  Asian Pac J Cancer Prev       Date:  2020-04-01

5.  Association Analysis of Methylenetetrahydrofolate Reductase Common Gene Polymorphisms with Breast Cancer Risk in an Iranian Population: A Case-Control Study and a Stratified Analysis.

Authors:  Mohammad Karimian; Nasrin Rezazadeh; Tahereh Khamehchian
Journal:  Asian Pac J Cancer Prev       Date:  2020-09-01

6.  Association of ApaI and TaqI polymorphisms in VDR Gene with Breast Cancer.

Authors:  Amir Hassan Matini; Negar Jafarian-Dehkordi; Banafshe Bahmani; Mehran Sharifi; Danial Jahantigh; Tahereh Mazoochi
Journal:  Asian Pac J Cancer Prev       Date:  2020-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.